Surgical outcomes of pulmonary metastasectomy for head and neck cancer in the current era of advances in chemotherapy and immunotherapy.
Head and neck cancer
Pulmonary metastasectomy
Surgical outcome
Journal
General thoracic and cardiovascular surgery
ISSN: 1863-6713
Titre abrégé: Gen Thorac Cardiovasc Surg
Pays: Japan
ID NLM: 101303952
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
30
11
2020
accepted:
26
02
2021
pubmed:
24
3
2021
medline:
20
7
2021
entrez:
23
3
2021
Statut:
ppublish
Résumé
The innovation of novel systemic chemo/immunotherapy for metastatic head and neck cancer might contribute to prognostic improvement. We aimed to clarify the recent characteristics and outcomes of pulmonary metastasectomy for head and neck cancer. Twenty-five patients who underwent pulmonary metastasectomy from January 2011 to December 2016 were included. The clinicopathological factors and survival were assessed by retrospective chart reviews. The median follow-up period was 39 months (range, 7-94 months). The median age was 66 years (range, 20-89 years), and 23 males were included. The primary tumor locations were as follows: pharynx (n = 12), nasal/paranasal cavity (n = 5), larynx (n = 4), and others (n = 4). The 5-year overall survival rate was 49%. In the univariate analysis, a history of local recurrence before pulmonary metastasis was an independent predictor of a poor prognosis. In 90% of patients with recurrence after pulmonary metastasectomy, the site of recurrence was the lung. Eight patients achieved long-term survival without any evidence of recurrence (median: 45 months). Molecular targeting chemotherapy and immune-checkpoint inhibitors were used in five patients with systemic recurrence after pulmonary metastasectomy, leading to preferable survival. In the current era of advances in systemic chemotherapy and immunotherapy, surgical indication has not changed for resectable pulmonary metastases and selected patients can still benefit from pulmonary metastasectomy. Further investigation is needed to clarify the significance of systemic therapy in patients with pulmonary metastasis of head and neck cancer.
Identifiants
pubmed: 33754238
doi: 10.1007/s11748-021-01611-7
pii: 10.1007/s11748-021-01611-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1214-1221Informations de copyright
© 2021. The Japanese Association for Thoracic Surgery.
Références
Network NCC. NCCN clinical practice guidelines in oncology (NCCN guidelines
Winter H, Meimarakis G, Hoffmann G, Hummel M, Rüttinger D, Zilbauer A, et al. Does surgical resection of pulmonary metastases of head and neck cancer improve survival? Ann Surg Oncol. 2008;15:2915–26.
doi: 10.1245/s10434-008-0001-4
Chen F, Sonobe M, Sato K, Fujinaga T, Shoji T, Sakai H, et al. Pulmonary resection for metastatic head and neck cancer. World J Surg. 2008;32:1657–62.
doi: 10.1007/s00268-008-9631-8
Shiono S, Kawamura M, Sato T, Okumura S, Nakajima J, Yoshino I, et al. Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas. Ann Thorac Surg. 2009;88:856–60.
doi: 10.1016/j.athoracsur.2009.04.040
Daiko H, Nagai K, Yoshida J, Nishimura M, Hishida T, Ebihara M, et al. The role of pulmonary resection in tumors metastatic from head and neck carcinomas. Jpn J Clin Oncol. 2010;40:639–44.
doi: 10.1093/jjco/hyq023
Haro A, Yano T, Yoshida T, Ito K, Morodomi Y, Shoji F, et al. Results of a surgical resection of pulmonary metastasis from malignant head and neck tumor. Interact Cardiovasc Thorac Surg. 2010;10:700–3.
doi: 10.1510/icvts.2009.219766
Miyazaki T, Hasegawa Y, Hanai N, Ozawa T, Hirakawa H, Suzuki A, et al. Survival impact of pulmonary metastasectomy for patients with head and neck cancer. Head Neck. 2013;35:1745–51.
doi: 10.1002/hed.23232
Yamazaki K, Shodo R, Ueki Y, Matsuyama H, Takahashi S. Therapeutic outcome after resection of pulmonary metastasis from head and neck carcinomas. Indian J Otolaryngol Head Neck Surg. 2015;67:124–8.
doi: 10.1007/s12070-014-0799-y
Yotsukura M, Kinoshita T, Kohno M, Asakura K, Kamiyama I, Emoto K, et al. Survival predictors after resection of lung metastases of head or neck cancers. Thorac Cancer. 2015;6:579–83.
doi: 10.1111/1759-7714.12225
Nakajima Y, Iijima Y, Kinoshita H, Akiyama H, Beppu T, Uramoto H, et al. Surgical treatment for pulmonary metastasis of head and neck cancer: study of 58 cases. Ann Thorac Cardiovasc Surg. 2017;23:169–74.
doi: 10.5761/atcs.oa.16-00269
Okada S, Itoh K, Ishihara S, Shimada J, Kato D, Tsunezuka H, et al. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma. Surg Oncol. 2018;27:259–65.
doi: 10.1016/j.suronc.2018.04.007
Oki T, Hishida T, Yoshida J, Goto M, Sekihara K, Miyoshi T, et al. Survival and prognostic factors after pulmonary metastasectomy of head and neck cancer: what are the clinically informative prognostic indicators? Eur J Cardiothorac Surg. 2019;55:942–7.
doi: 10.1093/ejcts/ezy384
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.
doi: 10.1056/NEJMoa0802656
Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646–54.
doi: 10.1200/JCO.2005.02.4646
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67.
doi: 10.1056/NEJMoa1602252
Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956–65.
doi: 10.1016/S1470-2045(16)30066-3
McCormack PM, Bains MS, Beattie EJ Jr, Martini N. Pulmonary resection in metastatic carcinoma. Chest. 1978;73:163–6.
doi: 10.1378/chest.73.2.163
Young ER, Diakos E, Khalid-Raja M, Mehanna H. Resection of subsequent pulmonary metastases from treated head and neck squamous cell carcinoma: systematic review and meta-analysis. Clin Otolaryngol. 2015;40:208–18.
doi: 10.1111/coa.12348
Geurts TW, van Velthuysen ML, Broekman F, van Huysduynen TH, van den Brekel MW, van Zandwijk N, et al. Differential diagnosis of pulmonary carcinoma following head and neck cancer by genetic analysis. Clin Cancer Res. 2009;15:980–5.
doi: 10.1158/1078-0432.CCR-08-1968
Ichinose J, Shinozaki-Ushiku A, Nagayama K, Nitadori JI, Anraku M, Fukayama M, et al. Immunohistochemical pattern analysis of squamous cell carcinoma: lung primary and metastatic tumors of head and neck. Lung Cancer. 2016;100:96–101.
doi: 10.1016/j.lungcan.2016.08.003
Muñoz-Largacha JA, Gower AC, Sridhar P, Deshpande A, O’Hara CJ, Yamada E, et al. miRNA profiling of primary lung and head and neck squamous cell carcinomas: addressing a diagnostic dilemma. J Thorac Cardiovasc Surg. 2017;154:714–27.
doi: 10.1016/j.jtcvs.2017.02.071
Bohnenberger H, Kaderali L, Ströbel P, Yepes D, Plessmann U, Dharia NV, et al. Comparative proteomics reveals a diagnostic signature for pulmonary head-and-neck cancer metastasis. EMBO Mol Med. 2018. https://doi.org/10.15252/emmm.201708428 .
doi: 10.15252/emmm.201708428
pubmed: 30097507
pmcid: 6127892